NEW YORK--(BUSINESS WIRE)-- Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime ...
Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of MRD capabilities – especially using QIAcuity digital PCR Tracer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results